Repository logo
 
Publication

Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions

2022Journal article Open access
Simple item page
dc.contributor.authorMendes‐Bastos, P
dc.contributor.authorBrasileiro, A
dc.contributor.authorKolkhir, P
dc.contributor.authorFrischbutter, S
dc.contributor.authorScheffel, J
dc.contributor.authorMoñino‐Romero, S
dc.contributor.authorMaurer, M
dc.date.accessioned2022-02-28T17:29:51Z
dc.date.available2022-02-28T17:29:51Z
dc.date.issued2022
dc.description.abstractBruton's tyrosine kinase (BTK), a member of the Tec kinase family, is critically involved in a range of immunological pathways. The clinical application of BTK inhibitors for B-cell malignancies has proven successful, and there is strong rationale for the potential benefits of BTK inhibitors in some autoimmune and allergic conditions, including immune-mediated dermatological diseases. However, the established risk-to-benefit profile of "first-generation" BTK inhibitors cannot be extrapolated to these emerging, non-oncological, indications. "Next-generation" BTK inhibitors such as remibrutinib and fenebrutinib entered clinical development for chronic spontaneous urticaria (CSU); rilzabrutinib and tirabrutinib are being studied as potential treatments for pemphigus. Promising data from early-phase clinical trials in CSU suggest potential for these agents to achieve strong pathway inhibition, which may translate into measurable clinical benefits, as well as other effects such as the disruption of autoantibody production. BTK inhibitors may help to overcome some of the shortcomings of monoclonal antibody treatments for immune-mediated dermatological conditions such as CSU, pemphigus, and systemic lupus erythematosus. In addition, the use of BTK inhibitors may improve understanding of the pathophysiological roles of mast cells, basophils, and B cells in such conditions.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationAllergy . 2022 Feb 17. doi: 10.1111/all.15261.pt_PT
dc.identifier.doi10.1111/all.15261pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.26/39581
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.subjectInibidores de Proteínas Quinasespt_PT
dc.subjectUrticáriapt_PT
dc.subjectPenfigopt_PT
dc.subjectProtein Kinase Inhibitorspt_PT
dc.subjectUrticariapt_PT
dc.subjectPemphiguspt_PT
dc.titleBruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditionspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.titleAllergypt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Allergy - 2022 - Mendes‐Bastos - Bruton s tyrosine kinase inhibition An emerging therapeutic strategy in immune‐mediated.pdf
Size:
906.58 KB
Format:
Adobe Portable Document Format
Download

Collections

Saúde - CUF - Descobertas - Artigos Científicos